CD8A and neoplasm: This therapy effectively promotes/recruits Type-1 anti-tumor CD8+ T cells into the TME and reduces immunologic indices associated with immune suppression, while as a consequence, approximately half of the animals receiving NLGP therapy demonstrated regressive disease.